I agree with both you and NS. I think it has been previously talked about limitedly on this board. Even if they didn’t do these screenings when initially starting leronlimab they could still compare the current patient data and see how it aligns with those in similar profiles (i.e. MDR 3 or mono who were on HAART for 5 years). If significantly better that would be a telling sign to potential BPs and internally to the company.

Maybe they are or have been doing this already, but my guess is that they have their hands full already and are not wasting their valuable time or money on this analysis.....much less if they is available data to compare the results to non-leronlimab patients to determine the baseline.